Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials
Related News

A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)

Phase 3
Completed
Conditions
Postoperative Dental Pain
First Posted Date
2008-06-10
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
588
Registration Number
NCT00694369

A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)

First Posted Date
2008-06-06
Last Posted Date
2024-05-09
Lead Sponsor
Organon and Co
Target Recruit Count
515
Registration Number
NCT00692913

Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)

Phase 4
Terminated
Conditions
Asthma
Interventions
Drug: Mometasone Furoate
First Posted Date
2008-05-30
Last Posted Date
2024-05-24
Lead Sponsor
Organon and Co
Target Recruit Count
385
Registration Number
NCT00687531

Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

First Posted Date
2008-05-05
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
3
Registration Number
NCT00671528

Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)

Phase 2
Completed
Conditions
Asthma
First Posted Date
2008-04-25
Last Posted Date
2024-05-10
Lead Sponsor
Organon and Co
Target Recruit Count
134
Registration Number
NCT00666679

Exercise Induced Bronchoconstriction (0476-359)

Phase 1
Completed
Conditions
Asthma, Exercise-induced
Interventions
Drug: montelukast sodium
First Posted Date
2008-04-23
Last Posted Date
2024-05-09
Lead Sponsor
Organon and Co
Target Recruit Count
24
Registration Number
NCT00664937

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

Phase 4
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: ezetimibe (+) simvastatin
First Posted Date
2008-04-08
Last Posted Date
2024-05-22
Lead Sponsor
Organon and Co
Target Recruit Count
173
Registration Number
NCT00654628

Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)

Phase 3
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Ezetimibe
Drug: Simvastatin
First Posted Date
2008-04-07
Last Posted Date
2024-05-21
Lead Sponsor
Organon and Co
Target Recruit Count
151
Registration Number
NCT00653523

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Phase 1
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: SCH 58235
Drug: pitavastatin
First Posted Date
2008-04-07
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
18
Registration Number
NCT00653913

Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)

Phase 3
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Ezetimibe
Drug: atorvastatin
First Posted Date
2008-04-07
Last Posted Date
2024-05-21
Lead Sponsor
Organon and Co
Target Recruit Count
146
Registration Number
NCT00654095
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy